

Gothenburg 2011-06-15

As a consultant in oncology I meet daily patients affected by side effects of chemotherapy or radiation therapy. One of the most distressing and prevalent side effect is derived from the injury to the intestinal tract. The lining of the intestinal tract is rapidly renewed in order to maintain a first line of defense against the **potentially** harmful contents of the intestinal tract (e.g. bacteria and other microorganisms). However, cancer therapy does not only arrest the proliferation of cancer cells but also the renewal of rapidly dividing normal tissue cells. Therefore, side effects from the intestinal tract (such as diarrhea or infections caused by the passage of intestinal microorganisms through the damaged intestinal lining) are common and can result in grave or even life threatening consequences (severe diarrhea and/or disseminated infections). There is today no effective prophylaxis against these side effects.

This first line of defense is also dependent on several components such as Immunoglobulin A which, during normal conditions, are produced by the cells of the intestine. Colostrum contains many of these components and, accordingly, is it my strong belief that colostrum delivered as ColoPlus *ONCARE* could reinforce the above described first line of defense and thereby reduce the side effects after chemotherapy or radiation therapy.

We are presently conducting explorative studies with ColoPlus *ONCARE*. If we can demonstrate beneficial effects of ColoPlus such an observation will have a tremendous impact on the patient's quality of life during therapy. Further, by avoiding hospitalization resource utilization could be improved. Finally, which also remains to be proven, the anticipated therapeutic efficacy could be preserved by accomplishing the scheduled therapy without dose reductions or interruptions.

Tor Ekman MD, PhD, Associate Professor
Department of Oncology
Sahlgrenska University Hospital,
Gothenburg, Sweden